EICHORCondition: Non-Small Cell Lung Cancer · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
This description comes directly from the study's public registry record.
Yijun Jia · +0518-81220121 · Yijun.jia@hengrui.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Aged 18-75 years 2. ECOG performance status score of 0 or 1; 3. Histopathologically confirmed advanced or metastatic non-small cell lung cancer; 4. Participants must provide archived or fresh tumor tissue; 5. Participants must have experienced disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease; 6. At least one measurable lesion according to RECIST v1.1 criteria; 7. Expected survival ≥3 months; 8. Adequate organ function; Exclusion Criteria: 1. Central nervous system metastasis or meningeal metastasis with clinical symptoms 2. History of or concurrent other malignancies; 3. Untreated spinal cord compression ; 4. Uncontrolled tumor-related pain; 5. Adverse events (AEs) from prior therapy not recovered to CTCAE Grade ≤1; 6. History of interstitial lung disease; 7. Severe cardiovascular/cerebrovascular diseases;
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Affiliated Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07489716